Status:
UNKNOWN
Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis
Lead Sponsor:
Changhai Hospital
Conditions:
Explore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver Metastases
Eligibility:
All Genders
18-70 years
Brief Summary
Accumulating evidence indicates that patient- derived organoids (PDOs) can predict drug responses in the clinic. Metastasis is the main cause of death in colorectal cancer patients, and the treatment ...
Eligibility Criteria
Inclusion
- Histologically proven colorectal cancer with liver metastasis
- Aged between 18 and 70 years
- Written informed and signed consent
- Accessible to surgery sample of metastasis and primary tumor
Exclusion
- Less than 18 years and older than 70 years
- Not able to give informed consent
- Not accessible to surgery sample
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05183425
Start Date
January 1 2022
End Date
December 31 2024
Last Update
February 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Colorectal Surgery in Changhai Hospital
Shanghai, Shanghai Municipality, China, 200433